Literature DB >> 6135395

Vasoactive and beta-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent.

Y Uchida, M Nakamura, S Shimizu, Y Shirasawa, M Fujii.   

Abstract

Single oral administration of K-351 showed a long lasting antihypertensive action in spontaneously hypertensive rats, accompanied by slight bradycardia. K-351 reduced systolic and diastolic blood pressures almost to the same degree. K-351 showed a competitive antagonistic effect on norepinephrine-induced contraction of isolated canine blood vessels. This alpha-adrenoceptor blocking action of K-351 was about 5 times less potent than that of phentolamine. Furthermore, K-351 produced a nitroglycerin-like relaxant action on isolated blood vessels previously contracted with high K+. K-351 showed a nonselective beta-adrenoceptor blocking action in isolated guinea-pig atrium and trachea, and its action was about 2 times more potent than that of propranolol. K-351 did not show an intrinsic sympathomimetic action. In anesthethized dogs, low doses of K-351 reduced the heart rate and antagonized the positive chronotropic and hypotensive responses to isoproterenol. In higher doses, K-351 lowered the blood pressure and showed an antagonistic action on the pressor response to phenylephrine. The desnitro compound of K-351 was deprived of vasoactive properties on isolated blood vessels and hypotensive activity. Results have revealed that K-351 has both beta-adrenoceptor blocking and vasoactive properties which may result in an antihypertensive effect without reflex tachycardia in hypertensive animals.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135395

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  14 in total

Review 1.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

2.  Adrenergic receptor effects and antihypertensive actions of beta-adrenoceptor-blocking agents with ancillary properties.

Authors:  S Imai; H Nakahara; M Nakazawa; K Takeda
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Cardioprotective and antiarrhythmic effects of beta-blockers, propranolol, bisoprolol, and nipradilol in a canine model of regional ischemia.

Authors:  T Ogawa; N Hieda; S Sugiyama; T Ito; T Satake; T Ozawa
Journal:  Heart Vessels       Date:  1989       Impact factor: 2.037

4.  Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans.

Authors:  M Kanno; M Araie; H Koibuchi; K Masuda
Journal:  Br J Ophthalmol       Date:  2000-03       Impact factor: 4.638

5.  Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: subgroup and subfield analyses of the nipradilol-timolol study.

Authors:  Makoto Araie; Shiroaki Shirato; Yoshio Yamazaki; Yoshiaki Kitazawa; Yasuo Ohashi
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

6.  Nipradilol, a new beta-adrenergic blocker, reduces left ventricular remodeling following myocardial infarction in spontaneously hypertensive rats.

Authors:  H Sonoki; M Nakamura; A Takeshita
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

Review 7.  Pharmacological profile of beta-adrenoceptor blockers with vasodilating properties, especially carvedilol--rationale for clinical use.

Authors:  G Sponer; W Bartsch; K Strein
Journal:  Clin Investig       Date:  1992

8.  Effects of nipradilol on myocardial ischaemia produced by coronary stenosis in dogs.

Authors:  K Noguchi; M Sakanashi
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

9.  Effects of Aging and Liver Disease upon the Pharmacokinetics of Nipradilol.

Authors:  T Aramaki; Y Katsuta; T Sekiyama; H Tsutsui; H Kome-Ichi; M Ohsuga; K Satomura; M Yoshimura
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

10.  Clinical efficacy of topical nipradilol and timolol on visual field performance in normal-tension glaucoma: a multicenter, randomized, double-masked comparative study.

Authors:  Makoto Araie; Shiroaki Shirato; Yoshio Yamazaki; Yoshiaki Kitazawa; Yasuo Ohashi
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.